Women | Men | |||
OR* (95% CI) | P value | OR* (95% CI) | P value | |
BMInaive, one unit decrease | 1.20 (1.00 to 1.43) | 0.046 | 0.8 (0.47 to 1.28) | 0.338 |
Age at onset (ref: <20) | 1 (reference) | – | 1 (reference) | – |
20–29 | 1.09 (0.22 to 5.40) | 0.135 | 0.05 (<0.001 to 4.50) | 0.201 |
30–39 | 1.3 (0.28 to 6.05) | 0.214 | 0.13 (0.002 to 4.37) | 0.253 |
40–49 | 3.37 (0.58 to 19.63) | 0.552 | 0.33 (0.002 to 31.18) | 0.621 |
50- | 15.67 (1.44 to 171.12) | 0.031 | 3.42 (0.057 to 839.73) | 0.558 |
*Binary logistic regression (reference: MS). Control variables included BMI, age at onset (categorised every 10 years). BMInaive, which is measured within 1 month of their disease onset and measured before the use of steroid treatment.
BMInaive, body mass index is measured within 1 month of their disease onset and measured before the use of steroid treatment; NMOSD-AQP4, neuromyelitis optica spectrum disorder with aquaporin-4 immunoglobulin G.